Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEECur trial in recurrent or refractory Ewing sarcoma
NL-OMON55584Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Dec 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ifosfamide, carboplatin, etoposide, lenvatinib, topotecan and 5 more in Ewing sarcoma and Ewing-like sarcoma (6 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Dec 2017; status: recruiting.
02
Drugs
ifosfamidecarboplatinetoposidelenvatinibtopotecan
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on NL-OMON55584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55584.